Participant flow

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression · Source last updated 2024-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received single-agent mirvetuximab soravtansine (MIRV) at 6 milligrams (mg)/kilogram (kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of every 3-week cycle (Q3W).

   id

   FG000

   title

   Mirvetuximab Soravtansine

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         62

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Other than specified

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         106

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         105

      type

      INV Efficacy Evaluable Population

   3. achievements

      1. group Id

         FG000

         num Subjects

         38

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         68

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Participants were enrolled at 39 sites in North America, Europe, and Asia Pacific.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice